ATHENS, Greece, via ETELIGIS INC., 01/26/2015 – – HCi Viocare (OTCQB: VICA), (the "Company") announced today that it has strengthened its management team with the arrival of new COO Heleen Kist and Investor Relations executive Mikuláš Dylowicz, who has been retained as a consultant. The appointments come at a time of operational growth for the company, which is setting up a chain of Prosthetic, Orthotic and Diabetic foot rehabilitation centres in Europe and progressing an R&D portfolio of devices for the wider health & wellbeing industry.
Heleen Kist is a former McKinsey consultant, in its Healthcare practice, and Procter & Gamble technical manager. Prior to joining HCi Viocare, she was an independent strategy consultant for over a decade and previously a VC investor and start-up CEO. She holds a MS in Management Science and Engineering from Stanford University and an MS in Chemistry from Leiden University in the Netherlands. Heleen will be based in HCi Viocare in the company’s R&D centre in Glasgow, UK.
Mikuláš Dylowicz co-founded private client investment advisory firm Milton Crown s.r.o. following an early career as financial advisor at Capital Partners a.s. in the Czech Republic. He studied Economics at the Czech University of Pardubice. Mikuláš is based in the Company’s office in Athens, Greece.
About HCi Viocare:
HCi Viocare has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants.
The company is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D centre in Glasgow, UK.
On behalf of the Board of Directors of HCi Viocare
Sotirios Leontaritis,
Chief Executive Officer and President
Forward Looking Statements:
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies. There is no assurance that the Company will be successful in its ongoing expansion and development efforts. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
CONTACT:
HCi Viocare
Sotiris Leontaritis, President
For further information about HCi Viocare please visit the Company’s website at http://www.viocare.eu
SOURCE: HCi Viocare
Yah00 Small Cap Market 